Literature DB >> 2041851

Hyperhomocysteinaemia and multiple aneurysms.

N Colwell1, R Clarke, K Robinson, F Keane, S O'Briain, I Graham.   

Abstract

Homozygous homocystinuria, the most common genetic disorder of transulphuration, is associated with elevated plasma concentrations of homocystine, homocysteine, multiple clinical abnormalities and life-threatening thromboembolism. Several instances of vascular aneurysms have also been documented. More recently, an association between premature occlusive vascular disease and the heterozygous state has been proposed. We now report an unusual case in whom multiple aneurysms were associated with heterozygous homocystinuria.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2041851      PMCID: PMC2398974          DOI: 10.1136/pgmj.67.784.186

Source DB:  PubMed          Journal:  Postgrad Med J        ISSN: 0032-5473            Impact factor:   2.401


  5 in total

1.  Vascular disease and homocysteine metabolism.

Authors:  S H Mudd
Journal:  N Engl J Med       Date:  1985-09-19       Impact factor: 91.245

2.  Abdominal aortic aneurysm in homocystinuria.

Authors:  B Almgren; I Eriksson; A Hemmingsson; G Hillerdal; E Larsson; H Aberg
Journal:  Acta Chir Scand       Date:  1978

3.  Unique efficiency of methionine metabolism in premenopausal women may protect against vascular disease in the reproductive years.

Authors:  G H Boers; A G Smals; F J Trijbels; A I Leermakers; P W Kloppenborg
Journal:  J Clin Invest       Date:  1983-12       Impact factor: 14.808

4.  The natural history of homocystinuria due to cystathionine beta-synthase deficiency.

Authors:  S H Mudd; F Skovby; H L Levy; K D Pettigrew; B Wilcken; R E Pyeritz; G Andria; G H Boers; I L Bromberg; R Cerone
Journal:  Am J Hum Genet       Date:  1985-01       Impact factor: 11.025

5.  Heterozygosity for homocystinuria in premature peripheral and cerebral occlusive arterial disease.

Authors:  G H Boers; A G Smals; F J Trijbels; B Fowler; J A Bakkeren; H C Schoonderwaldt; W J Kleijer; P W Kloppenborg
Journal:  N Engl J Med       Date:  1985-09-19       Impact factor: 91.245

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.